STAT+: Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data
Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for…
Category: Biogen
STAT+: The biotech scorecard for the third quarter: 19 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A spending frenzy on obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Looking for signs of growth in Biogen’s earnings
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the…
STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second…
Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon
What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a…
STAT+: Years after a polarizing approval, Biogen walks away from Aduhelm
Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval…
STAT+: Biogen shutters digital health group, nixes Apple study, as part of cost cuts
Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person…